PsychoactiveMap

Toronto Western Hospital psychedelic research trials

Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

Toronto Western Hospital is listed with 5 registered studies counted here, in Toronto, Canada. By compound: 2 psilocybin and 3 ketamine. By registry status: 1 recruiting, 1 enrolling by invitation, 1 active, not recruiting and 2 completed. By phase: 4 phase 2 and 1 not applicable. Reported start years run from 2022 (earliest) to 2026 (latest).

Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

At a glance

By compound

Compound hubStudies
Psilocybin2
Ketamine3

By registry status

StatusStudiesShare
Recruiting120%
Enrolling by invitation120%
Active, not recruiting120%
Completed240%

By phase

PhaseStudiesShare
Phase 2480%
Not applicable120%

Registered studies

All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesCompound
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionNCT07737990Enrolling by invitationNot applicableSource start: 2026-07-01 (estimated)
Source date details

Start: 2026-07-01 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2029-12-31 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2030-06-30 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-07-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)NCT07569198RecruitingPhase 2Source start: 2026-07-16 (estimated)
Saved start 2026-06-01 differs from reported 2026-07-16; the saved day is not established by this observation.
Source date details

Start: 2026-07-16 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2029-01 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2029-08 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-07-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of PsilocybinNCT06341426Active, not recruitingPhase 2Source start: 2024-02-05 (actual)
Source date details

Start: 2024-02-05 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-07-28 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2026-12-28 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2026-07-09 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Maintenance Ketamine Infusions for Treatment-Resistant Bipolar DepressionNCT05339074CompletedPhase 2Source start: 2022-08-11 (actual)
Source date details

Start: 2022-08-11 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-01-28 (precision: day; source type: ACTUAL; actual)

Study completion: 2026-01-28 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Ketamine for Treatment-Resistant Bipolar DisorderNCT05004896CompletedPhase 2Source start: 2022-07-04 (actual)
Source date details

Start: 2022-07-04 (precision: day; source type: ACTUAL; actual)

Primary completion: 2025-11-14 (precision: day; source type: ACTUAL; actual)

Study completion: 2025-11-14 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:15.858Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | Ketamine

Country hub: Canada

All trial hubs | Learn | Disclaimer